 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 February 1998 | Volume 128 Issue 4 | Pages 306-312
Until recently, patients had little motivation to seek medical care soon after sexual exposure to HIV.However, evidence that antiretroviral treatment prevents HIV infection after occupational exposure has led to the recommendation that prophylaxis be considered after sexual exposure. This recommendation will result in an increased number of recently exposed patients presenting for care. Clinicians should seize this opportunity to reach persons who are at high risk for HIV seroconversion and provide them with evaluation, treatment, and counseling. A comprehensive approach to the care of persons recently exposed to HIV is proposed. Candidates for postexposure prophylaxis should be identified and given appropriate antiretroviral treatment. Physicians must perform HIV antibody testing to determine which persons are already infected with HIV and must do baseline laboratory studies. Follow-up care includes assessment of side effects from postexposure treatment and surveillance for development of primary HIV infection. Most important, clinicians must provide risk-reduction counseling to decrease the chance of future exposures. Public health messages must emphasize that postexposure treatment should be used only as a backup for failure of primary prevention methods, such as avoidance of high-risk sexual exposures or use of condoms.
Author and Article Information
From the San Francisco Department of Public Health and the University of California, San Francisco, San Francisco, California.
PERSPECTIVE
The Care of Persons with Recent Sexual Exposure to HIV
Note: Drs. Katz and Gerberding are investigators for "Postexposure Prophylaxis: Feasibility and Consequences," a study funded by the National Institute for Allergy and Infectious Diseases. Glaxo Wellcome, Bristol-Meyers Squibb, and Agouron Pharmaceuticals also agreed to provide drug or financial support. Drs. Katz and Gerberding receive no direct financial support from the pharmaceutical companies, and the companies did not contribute in any way to the writing of or the decision to publish the current report.
Acknowledgments: The authors thank Susan Buchbinder, MD, and Joshua Bamberger, MD, for comments on earlier drafts of this manuscript.
Grant Support: In part by Glaxo Wellcome, Pfizer, and Merck (Dr. Gerberding).
Requests for Reprints: Mitchell H. Katz, MD, 101 Grove Street, Room 308, San Francisco, CA 94102.
Current Author Addresses: Dr. Katz: 101 Grove Street, Room 308, San Francisco, CA 94102.
This article has been cited by other articles:
|
|
 |
|
  L. S. Weinhardt Changing HIV and AIDS-Related Behavior: Promising Approaches at the Individual, Group, and Community Levels Behav Modif, March 1, 2005; 29(2): 219 - 226. [PDF]
|
|
|
|
 |
|
 S. D. Pinkerton, J. N. Martin, M. E. Roland, M. H. Katz, T. J. Coates, and J. O. Kahn Cost-effectiveness of Postexposure Prophylaxis After Sexual or Injection-Drug Exposure to Human Immunodeficiency Virus Arch Intern Med, January 12, 2004; 164(1): 46 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Havens and Committee on Pediatric AIDS Postexposure Prophylaxis in Children and Adolescents for Nonoccupational Exposure to Human Immunodeficiency Virus Pediatrics, June 1, 2003; 111(6): 1475 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Merchant and R. Keshavarz Human Immunodeficiency Virus Postexposure Prophylaxis for Adolescents and Children Pediatrics, August 1, 2001; 108 (2): e38 - e38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Fong Post-exposure prophylaxis for HIV infection after sexual assault: When is it indicated? Emerg. Med. J., July 1, 2001; 18(4): 242 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. E. Babl, E. R. Cooper, B. Kastner, and S. Kharasch Prophylaxis Against Possible Human Immunodeficiency Virus Exposure After Nonoccupational Needlestick Injuries or Sexual Assaults in Children and Adolescents Arch Pediatr Adolesc Med, June 1, 2001; 155(6): 680 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Nonoccupational Postexposure Prophylaxis: Evolving Clinical Practice AIDS Clinical Care, January 1, 2000; 2000(101): 3 - 3. [Full Text]
|
|
|
|
 |
|
 S. J. Little, A. R. McLean, C. A. Spina, D. D. Richman, and D. V. Havlir Viral Dynamics of Acute HIV-1 Infection J. Exp. Med., September 20, 1999; 190(6): 841 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Atabaki and J. E. Paradise The Medical Evaluation of the Sexually Abused Child: Lessons From a Decade of Research Pediatrics, July 1, 1999; 104(1): 178 - 178. [Full Text]
|
|
|
|
 |
|
 D. K. Henderson Postexposure Chemoprophylaxis for Occupational Exposures to the Human Immunodeficiency Virus JAMA, March 10, 1999; 281(10): 931 - 936. [Full Text] [PDF]
|
|
|
|
|
|
P. Lurie, S. Miller, F. Hecht, M. Chesney, and B. Lo Postexposure Prophylaxis After Nonoccupational HIV Exposure: Clinical, Ethical, and Policy Considerations JAMA, November 25, 1998; 280(20): 1769 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. J. Carpenter, M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, et al. Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society-USA Panel JAMA, July 1, 1998; 280(1): 78 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Post-Sexual Exposure Prophylaxis: A Roundtable Discussion AIDS Clinical Care, February 1, 1998; 1998(201): 1 - 1. [Full Text]
|
|
Article
